26.  Plaintiff brings this action pursuant to Federal Rule of Civil Procedure 23, individually  and on behalf of the stockholders of Proteostasis’ common stock who are being and will be harmed by  Defendants’ actions described herein (the “Class”).  The Class specifically excludes Defendants herein,  and any person, firm, trust, corporation or other entity related to, or affiliated with, any of the  Defendants.   34.  Proteostasis engages in the discovery and development of novel therapeutics to treat  Cystic Fibrosis (“CF”). The Company's lead product candidates for the treatment of CF include PTI- 801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR  potentiator; and PTI-428, a CFTR amplifier. The Company has collaboration agreements with the  Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of  CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and  Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule  modulators.   35.  On June 1, 2020, the Company announced it was evaluating its PTI-129 cystic fibrosis  drug as a treatment for COVID-19.    36.  Speaking on the possibility and need of these studies, Defendant Chhabra, President and  CEO of Proteostasis, stated, “The ongoing COVID-19 pandemic is a public health crisis that demands  the investigation of all possible avenues of resolution," said Defendant Chhabra, ‘We are exploring  ways to further our understanding of PTI-129's potential in fighting COVID-19, and are seeking support  from governmental agencies to accelerate this program.” Vice President Chatterjee added, “The urgent  need to develop effective treatments against COVID-19 is a global priority, and Calibr is committed to  studying a broad spectrum of compounds and pathways, such as the UPR modulator, PTI-129, in the  fight against this disease.”   85.  Plaintiff repeats all previous allegations as if set forth in full herein.   86.  The Individual Defendants have violated their fiduciary duties of care, loyalty and good  faith owed to Plaintiffs and the Company’s public stockholders.   96.  Plaintiff incorporates each and every allegation set forth above as if fully set forth herein.   97.  Defendants Proteostasis and Yumanity knowingly assisted the Individual Defendants’  breaches of fiduciary duty in connection with the Proposed Transaction, which, without such aid, would  not have occurred   98.  As a result of this conduct, Plaintiff and the other members of the Class have been and  will be damaged in that they have been and will be prevented from obtaining a fair price for their shares.   99.  Plaintiff and the members of the Class have no adequate remedy at law.  Aiding and Abetting the Board’s Breaches of Fiduciary Duty   (Against Defendants Proteostasis and Yumanity)   Claim for Breach of Fiduciary Duties  (Against the Individual Defendants)   Company Background  